Sanofi nabs FDA approval for Kynamro, despite safety concerns

The FDA came through with an approval for Kynamro, a treatment for a rare form of high cholesterol from Sanofi's ($SNY) Genzyme unit. But the agency's blessing came with some strings attached: Four post-marketing studies and long-term safety tracking. Report